×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Peptide Receptor Radionuclide Therapy Market

ID: MRFR/Pharma/35169-HCR
100 Pages
Rahul Gotadki
October 2025

Informe de investigación de mercado de PRRT de terapia con radionúclidos con receptores de péptidos por indicación (tumores neuroendocrinos, cáncer de próstata, feocromocitoma, tumores carcinoides gástricos), por tipo de terapia (radiofármacos terapéuticos, radiofármacos de diagnóstico, terapia combinada), por vía de administración (intravenosa, subcutánea), por usuario final (hospitales, clínicas especializadas, institutos de investigación) y por región (América del Norte, Europa, Sudamérica, Asia Pacífico, Medio Oriente y África) - Previsi... leer más

Compartir
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Peptide Receptor Radionuclide Therapy Market Infographic
Purchase Options

Peptide Receptor Radionuclide Therapy Market Resumen

Las empresas clave en el mercado Peptide Receptor Radionuclide Therapy Market incluyen

Alcance del informe

Deja un comentario

FAQs

What is the current market valuation of the Peptide Receptor Radionuclide Therapy (PRRT) market?

The Peptide Receptor Radionuclide Therapy market was valued at 2.848 USD Billion in 2024.

What is the projected market size for PRRT by 2035?

The market is expected to reach 7.335 USD Billion by 2035.

What is the expected CAGR for the PRRT market during the forecast period 2025 - 2035?

The expected CAGR for the PRRT market during 2025 - 2035 is 8.98%.

Which companies are the key players in the PRRT market?

Key players in the PRRT market include Novartis, Bayer, Ipsen, Advanced Accelerator Applications, Lantheus Medical Imaging, TheraP, Siemens Healthineers, and GE Healthcare.

What are the primary indications for PRRT?

The primary indications for PRRT include Neuroendocrine Tumors, Prostate Cancer, Pheochromocytoma, and Gastric Carcinoid Tumors.

How is the PRRT market segmented by type of therapy?

The PRRT market is segmented into Therapeutic Radiopharmaceuticals, Diagnostic Radiopharmaceuticals, and Combination Therapy.

What are the projected revenues for Neuroendocrine Tumors in the PRRT market by 2035?

Revenues for Neuroendocrine Tumors are projected to reach 3.675 USD Billion by 2035.

What is the expected revenue for hospitals as end users of PRRT by 2035?

Hospitals are expected to generate revenues of 3.675 USD Billion as end users of PRRT by 2035.

What administration routes are utilized in the PRRT market?

The PRRT market utilizes both Intravenous and Subcutaneous administration routes.

How does the revenue for specialized clinics compare to hospitals in the PRRT market by 2035?

By 2035, specialized clinics are projected to generate 2.215 USD Billion, which is significantly lower than the 3.675 USD Billion expected for hospitals.

Descargar muestra gratis

Complete el formulario a continuación para recibir una muestra gratuita de este informe

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions